Non-sleepy obstructive sleep apnoea: to treat or not to treat?

Non-sleepy obstructive sleep apnoea (OSA) is thought to have a prevalence of around 20–25% in industrialised countries. However, the question of whether it should be routinely treated or not is controversial. This review collates the results from recent randomised controlled trials addressing OSA an...

Descripción completa

Detalles Bibliográficos
Autores principales: Altintas, Nejat, Riha, Renata L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488974/
https://www.ncbi.nlm.nih.gov/pubmed/31871125
http://dx.doi.org/10.1183/16000617.0031-2019
_version_ 1784792780665520128
author Altintas, Nejat
Riha, Renata L.
author_facet Altintas, Nejat
Riha, Renata L.
author_sort Altintas, Nejat
collection PubMed
description Non-sleepy obstructive sleep apnoea (OSA) is thought to have a prevalence of around 20–25% in industrialised countries. However, the question of whether it should be routinely treated or not is controversial. This review collates the results from recent randomised controlled trials addressing OSA and examines whether treating the condition leads to improvements in quality of life and reduced cardiometabolic dysfunction, comorbidities generally attributed to untreated obstructive sleep apnoea/hypopnoea syndrome.
format Online
Article
Text
id pubmed-9488974
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-94889742022-11-14 Non-sleepy obstructive sleep apnoea: to treat or not to treat? Altintas, Nejat Riha, Renata L. Eur Respir Rev Series Non-sleepy obstructive sleep apnoea (OSA) is thought to have a prevalence of around 20–25% in industrialised countries. However, the question of whether it should be routinely treated or not is controversial. This review collates the results from recent randomised controlled trials addressing OSA and examines whether treating the condition leads to improvements in quality of life and reduced cardiometabolic dysfunction, comorbidities generally attributed to untreated obstructive sleep apnoea/hypopnoea syndrome. European Respiratory Society 2019-12-23 /pmc/articles/PMC9488974/ /pubmed/31871125 http://dx.doi.org/10.1183/16000617.0031-2019 Text en Copyright ©ERS 2019. https://creativecommons.org/licenses/by-nc/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Series
Altintas, Nejat
Riha, Renata L.
Non-sleepy obstructive sleep apnoea: to treat or not to treat?
title Non-sleepy obstructive sleep apnoea: to treat or not to treat?
title_full Non-sleepy obstructive sleep apnoea: to treat or not to treat?
title_fullStr Non-sleepy obstructive sleep apnoea: to treat or not to treat?
title_full_unstemmed Non-sleepy obstructive sleep apnoea: to treat or not to treat?
title_short Non-sleepy obstructive sleep apnoea: to treat or not to treat?
title_sort non-sleepy obstructive sleep apnoea: to treat or not to treat?
topic Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488974/
https://www.ncbi.nlm.nih.gov/pubmed/31871125
http://dx.doi.org/10.1183/16000617.0031-2019
work_keys_str_mv AT altintasnejat nonsleepyobstructivesleepapnoeatotreatornottotreat
AT riharenatal nonsleepyobstructivesleepapnoeatotreatornottotreat

Ejemplares similares